Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment

A study protocol

R. K. Charaghvandi, B. van Asselen, M. E P Philippens, H. M. Verkooijen, C. H. van Gils, P. J. van Diest, R. M. Pijnappel, M. G G Hobbelink, A. J. Witkamp, T. van Dalen, E. van der Wall, T. C. van Heijst, R. Koelemij, M. van Vulpen, H. J G D van den Bongard

Research output: Contribution to journalArticle

Abstract

Background: A shift towards less burdening and more patient friendly treatments for breast cancer is currently ongoing. In low-risk patients with early-stage disease, accelerated partial breast irradiation (APBI) is an alternative for whole breast irradiation following breast-conserving surgery. MRI-guided single dose ablative APBI has the potential to offer a minimally burdening, non-invasive treatment that could replace current breast-conserving therapy. Methods: The ABLATIVE study is a prospective, single arm, multicenter study evaluating preoperative, single dose, ablative radiation treatment in patients with early-stage breast cancer. Patients with core biopsy proven non-lobular invasive breast cancer, (estrogen receptor positive, Her2 negative, maximum tumor size 3.0 cm on diagnostic MRI) and a negative sentinel node biopsy are eligible. Radiotherapy (RT) planning will be performed using a contrast enhanced (CE) planning CT-scan, co-registered with a CE-MRI, both in supine RT position. A total of twenty-five consecutive patients will be treated with a single ablative RT dose of 20 Gy to the tumor and 15 Gy to the tumorbed. Follow-up MRIs are scheduled within 1 week, 2, 4 and 6 months after single-dose RT. Breast-conserving surgery is scheduled at six months following RT. Primary study endpoint is pathological complete response. Secondary study endpoints are the radiological response and toxicity. Furthermore, patients will fill out questionnaires on quality of life and functional status. Cosmetic outcome will be evaluated by the treating radiation oncologist, patient and 'Breast Cancer Conservation Treatment cosmetic results' software. Recurrence and survival rates will be assessed. The patients will be followed up to 10 years after diagnosis. If patients give additional informed consent, a biopsy and a part of the irradiated specimen will be stored at the local Biobank and used for future research on radiotherapy response associated genotyping. Discussion: The ABLATIVE study evaluates MRI-guided single dose ablative RT in patients with early-stage breast cancer, aiming at a less burdening and non-invasive alternative for current breast-conserving treatment. Trial registration: ClinicalTrials.gov registration number NCT02316561. The trial was registrated prospectively on October 10th 2014.

Original languageEnglish (US)
Article number181
JournalBMC Cancer
Volume17
Issue number1
DOIs
StatePublished - Mar 9 2017

Fingerprint

Radiotherapy
Breast Neoplasms
Breast
Therapeutics
Segmental Mastectomy
Biopsy
Cosmetics
Supine Position
Informed Consent
Estrogen Receptors
Multicenter Studies
Neoplasms
Arm
Software
Survival Rate
Quality of Life
Radiation
Recurrence

Keywords

  • Ablative
  • Breast cancer
  • MRI-guidance
  • Partial breast irradiation
  • Radiosurgery

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Charaghvandi, R. K., van Asselen, B., Philippens, M. E. P., Verkooijen, H. M., van Gils, C. H., van Diest, P. J., ... van den Bongard, H. J. G. D. (2017). Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: A study protocol. BMC Cancer, 17(1), [181]. https://doi.org/10.1186/s12885-017-3144-5

Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment : A study protocol. / Charaghvandi, R. K.; van Asselen, B.; Philippens, M. E P; Verkooijen, H. M.; van Gils, C. H.; van Diest, P. J.; Pijnappel, R. M.; Hobbelink, M. G G; Witkamp, A. J.; van Dalen, T.; van der Wall, E.; van Heijst, T. C.; Koelemij, R.; van Vulpen, M.; van den Bongard, H. J G D.

In: BMC Cancer, Vol. 17, No. 1, 181, 09.03.2017.

Research output: Contribution to journalArticle

Charaghvandi, RK, van Asselen, B, Philippens, MEP, Verkooijen, HM, van Gils, CH, van Diest, PJ, Pijnappel, RM, Hobbelink, MGG, Witkamp, AJ, van Dalen, T, van der Wall, E, van Heijst, TC, Koelemij, R, van Vulpen, M & van den Bongard, HJGD 2017, 'Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: A study protocol', BMC Cancer, vol. 17, no. 1, 181. https://doi.org/10.1186/s12885-017-3144-5
Charaghvandi RK, van Asselen B, Philippens MEP, Verkooijen HM, van Gils CH, van Diest PJ et al. Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: A study protocol. BMC Cancer. 2017 Mar 9;17(1). 181. https://doi.org/10.1186/s12885-017-3144-5
Charaghvandi, R. K. ; van Asselen, B. ; Philippens, M. E P ; Verkooijen, H. M. ; van Gils, C. H. ; van Diest, P. J. ; Pijnappel, R. M. ; Hobbelink, M. G G ; Witkamp, A. J. ; van Dalen, T. ; van der Wall, E. ; van Heijst, T. C. ; Koelemij, R. ; van Vulpen, M. ; van den Bongard, H. J G D. / Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment : A study protocol. In: BMC Cancer. 2017 ; Vol. 17, No. 1.
@article{6aca207165fc424696def6e5bd0cf10a,
title = "Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: A study protocol",
abstract = "Background: A shift towards less burdening and more patient friendly treatments for breast cancer is currently ongoing. In low-risk patients with early-stage disease, accelerated partial breast irradiation (APBI) is an alternative for whole breast irradiation following breast-conserving surgery. MRI-guided single dose ablative APBI has the potential to offer a minimally burdening, non-invasive treatment that could replace current breast-conserving therapy. Methods: The ABLATIVE study is a prospective, single arm, multicenter study evaluating preoperative, single dose, ablative radiation treatment in patients with early-stage breast cancer. Patients with core biopsy proven non-lobular invasive breast cancer, (estrogen receptor positive, Her2 negative, maximum tumor size 3.0 cm on diagnostic MRI) and a negative sentinel node biopsy are eligible. Radiotherapy (RT) planning will be performed using a contrast enhanced (CE) planning CT-scan, co-registered with a CE-MRI, both in supine RT position. A total of twenty-five consecutive patients will be treated with a single ablative RT dose of 20 Gy to the tumor and 15 Gy to the tumorbed. Follow-up MRIs are scheduled within 1 week, 2, 4 and 6 months after single-dose RT. Breast-conserving surgery is scheduled at six months following RT. Primary study endpoint is pathological complete response. Secondary study endpoints are the radiological response and toxicity. Furthermore, patients will fill out questionnaires on quality of life and functional status. Cosmetic outcome will be evaluated by the treating radiation oncologist, patient and 'Breast Cancer Conservation Treatment cosmetic results' software. Recurrence and survival rates will be assessed. The patients will be followed up to 10 years after diagnosis. If patients give additional informed consent, a biopsy and a part of the irradiated specimen will be stored at the local Biobank and used for future research on radiotherapy response associated genotyping. Discussion: The ABLATIVE study evaluates MRI-guided single dose ablative RT in patients with early-stage breast cancer, aiming at a less burdening and non-invasive alternative for current breast-conserving treatment. Trial registration: ClinicalTrials.gov registration number NCT02316561. The trial was registrated prospectively on October 10th 2014.",
keywords = "Ablative, Breast cancer, MRI-guidance, Partial breast irradiation, Radiosurgery",
author = "Charaghvandi, {R. K.} and {van Asselen}, B. and Philippens, {M. E P} and Verkooijen, {H. M.} and {van Gils}, {C. H.} and {van Diest}, {P. J.} and Pijnappel, {R. M.} and Hobbelink, {M. G G} and Witkamp, {A. J.} and {van Dalen}, T. and {van der Wall}, E. and {van Heijst}, {T. C.} and R. Koelemij and {van Vulpen}, M. and {van den Bongard}, {H. J G D}",
year = "2017",
month = "3",
day = "9",
doi = "10.1186/s12885-017-3144-5",
language = "English (US)",
volume = "17",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment

T2 - A study protocol

AU - Charaghvandi, R. K.

AU - van Asselen, B.

AU - Philippens, M. E P

AU - Verkooijen, H. M.

AU - van Gils, C. H.

AU - van Diest, P. J.

AU - Pijnappel, R. M.

AU - Hobbelink, M. G G

AU - Witkamp, A. J.

AU - van Dalen, T.

AU - van der Wall, E.

AU - van Heijst, T. C.

AU - Koelemij, R.

AU - van Vulpen, M.

AU - van den Bongard, H. J G D

PY - 2017/3/9

Y1 - 2017/3/9

N2 - Background: A shift towards less burdening and more patient friendly treatments for breast cancer is currently ongoing. In low-risk patients with early-stage disease, accelerated partial breast irradiation (APBI) is an alternative for whole breast irradiation following breast-conserving surgery. MRI-guided single dose ablative APBI has the potential to offer a minimally burdening, non-invasive treatment that could replace current breast-conserving therapy. Methods: The ABLATIVE study is a prospective, single arm, multicenter study evaluating preoperative, single dose, ablative radiation treatment in patients with early-stage breast cancer. Patients with core biopsy proven non-lobular invasive breast cancer, (estrogen receptor positive, Her2 negative, maximum tumor size 3.0 cm on diagnostic MRI) and a negative sentinel node biopsy are eligible. Radiotherapy (RT) planning will be performed using a contrast enhanced (CE) planning CT-scan, co-registered with a CE-MRI, both in supine RT position. A total of twenty-five consecutive patients will be treated with a single ablative RT dose of 20 Gy to the tumor and 15 Gy to the tumorbed. Follow-up MRIs are scheduled within 1 week, 2, 4 and 6 months after single-dose RT. Breast-conserving surgery is scheduled at six months following RT. Primary study endpoint is pathological complete response. Secondary study endpoints are the radiological response and toxicity. Furthermore, patients will fill out questionnaires on quality of life and functional status. Cosmetic outcome will be evaluated by the treating radiation oncologist, patient and 'Breast Cancer Conservation Treatment cosmetic results' software. Recurrence and survival rates will be assessed. The patients will be followed up to 10 years after diagnosis. If patients give additional informed consent, a biopsy and a part of the irradiated specimen will be stored at the local Biobank and used for future research on radiotherapy response associated genotyping. Discussion: The ABLATIVE study evaluates MRI-guided single dose ablative RT in patients with early-stage breast cancer, aiming at a less burdening and non-invasive alternative for current breast-conserving treatment. Trial registration: ClinicalTrials.gov registration number NCT02316561. The trial was registrated prospectively on October 10th 2014.

AB - Background: A shift towards less burdening and more patient friendly treatments for breast cancer is currently ongoing. In low-risk patients with early-stage disease, accelerated partial breast irradiation (APBI) is an alternative for whole breast irradiation following breast-conserving surgery. MRI-guided single dose ablative APBI has the potential to offer a minimally burdening, non-invasive treatment that could replace current breast-conserving therapy. Methods: The ABLATIVE study is a prospective, single arm, multicenter study evaluating preoperative, single dose, ablative radiation treatment in patients with early-stage breast cancer. Patients with core biopsy proven non-lobular invasive breast cancer, (estrogen receptor positive, Her2 negative, maximum tumor size 3.0 cm on diagnostic MRI) and a negative sentinel node biopsy are eligible. Radiotherapy (RT) planning will be performed using a contrast enhanced (CE) planning CT-scan, co-registered with a CE-MRI, both in supine RT position. A total of twenty-five consecutive patients will be treated with a single ablative RT dose of 20 Gy to the tumor and 15 Gy to the tumorbed. Follow-up MRIs are scheduled within 1 week, 2, 4 and 6 months after single-dose RT. Breast-conserving surgery is scheduled at six months following RT. Primary study endpoint is pathological complete response. Secondary study endpoints are the radiological response and toxicity. Furthermore, patients will fill out questionnaires on quality of life and functional status. Cosmetic outcome will be evaluated by the treating radiation oncologist, patient and 'Breast Cancer Conservation Treatment cosmetic results' software. Recurrence and survival rates will be assessed. The patients will be followed up to 10 years after diagnosis. If patients give additional informed consent, a biopsy and a part of the irradiated specimen will be stored at the local Biobank and used for future research on radiotherapy response associated genotyping. Discussion: The ABLATIVE study evaluates MRI-guided single dose ablative RT in patients with early-stage breast cancer, aiming at a less burdening and non-invasive alternative for current breast-conserving treatment. Trial registration: ClinicalTrials.gov registration number NCT02316561. The trial was registrated prospectively on October 10th 2014.

KW - Ablative

KW - Breast cancer

KW - MRI-guidance

KW - Partial breast irradiation

KW - Radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=85014745954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014745954&partnerID=8YFLogxK

U2 - 10.1186/s12885-017-3144-5

DO - 10.1186/s12885-017-3144-5

M3 - Article

VL - 17

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 181

ER -